Concord Biotech Limited (NSE:CONCORDBIO)

Concord Biotech Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	11,251	12,001	10,169	8,532	7,129	6,169
Revenue Growth (YoY)	3.63%	18.01%	19.20%	19.67%	15.56%	20.42%
Cost of Revenue	4,028	4,317	3,498	1,921	1,719	1,169
Gross Profit	7,224	7,684	6,672	6,611	5,410	5,000
Selling, General & Admin	1,560	1,389	1,230	1,103	956.96	694.73
Other Operating Expenses	1,200	1,150	1,038	1,969	1,662	1,001
Operating Expenses	3,400	3,083	2,805	3,612	3,120	1,976
Operating Income	3,824	4,601	3,867	2,999	2,290	3,024
Interest Expense	-3.11	-5.29	-25.52	-45.1	-54.84	-6.66
Interest & Investment Income	17.1	17.1	30.41	44.41	47.87	17.87
Earnings From Equity Investments	40.66	-13.22	33.71	19.59	-36.38	-4.49
Currency Exchange Gain (Loss)	81.98	81.98	64.81	102.22	63.59	15.51
Other Non Operating Income (Expenses)	110.51	43.54	12.79	57.93	9.73	11.25
EBT Excluding Unusual Items	4,071	4,725	3,983	3,178	2,320	3,057
Gain (Loss) on Sale of Investments	222.64	222.64	140.65	37.17	52.3	69.86
Gain (Loss) on Sale of Assets	-2.25	-2.25	0.12	-0.94	-0.34	-
Other Unusual Items	-	-	-	-0.31	-	-
Pretax Income	4,291	4,946	4,126	3,220	2,375	3,127
Income Tax Expense	1,057	1,229	1,045	819.28	625.89	778.33
Net Income	3,239	3,716	3,081	2,401	1,749	2,349
Net Income to Common	3,239	3,716	3,081	2,401	1,749	2,349
Net Income Growth	-1.21%	20.62%	28.33%	37.25%	-25.53%	38.89%
Shares Outstanding (Basic)	105	105	105	105	105	105
Shares Outstanding (Diluted)	105	105	105	105	105	105
EPS (Basic)	30.89	35.52	29.45	22.95	16.72	22.45
EPS (Diluted)	30.89	35.52	29.45	22.95	16.72	22.45
EPS Growth	-1.47%	20.62%	28.33%	37.25%	-25.52%	38.88%
Free Cash Flow	1,297	1,333	1,798	1,009	526.36	-373.59
Free Cash Flow Per Share	12.37	12.75	17.18	9.65	5.03	-3.57
Dividend Per Share	-	10.700	8.750	6.830	5.120	6.741
Dividend Growth	-	22.29%	28.11%	33.40%	-24.05%	63.87%
Gross Margin	64.20%	64.03%	65.61%	77.49%	75.89%	81.05%
Operating Margin	33.98%	38.34%	38.03%	35.15%	32.12%	49.01%
Profit Margin	28.79%	30.97%	30.30%	28.14%	24.54%	38.07%
Free Cash Flow Margin	11.53%	11.11%	17.68%	11.83%	7.38%	-6.06%
EBITDA	4,446	5,127	4,386	3,527	2,778	3,287
EBITDA Margin	39.52%	42.72%	43.13%	41.33%	38.97%	53.28%
D&A For EBITDA	622.82	526.08	518.51	527.85	487.98	263.27
EBIT	3,824	4,601	3,867	2,999	2,290	3,024
EBIT Margin	33.98%	38.34%	38.03%	35.15%	32.12%	49.01%
Effective Tax Rate	24.63%	24.85%	25.32%	25.44%	26.35%	24.89%
Revenue as Reported	11,763	12,445	10,507	8,885	7,364	6,308

Source: S&P Global Market Intelligence. Standard template. Financial Sources.